HB002.1M / Zhejiang Huahai Pharma, Huaota Biopharm, Huabo Biopharmaceutical Technology - LARVOL DELTA

[VIRTUAL] NEUROPROTECTION OF LOW DOSE CARBON MONOXIDE IN GENETIC AND TOXIN MODELS OF PARKINSON’S DISEASE (ADPD 2021) - "AAV-aSyn rats treated with HBI002 retained 74±12% (SD) of right striatal dopamine versus left, compared to 36±7% in vehicle-treated rats (p=0.03). Low-dose CO protects nigral dopamine neurons, preserves striatal dopamine content, and reduces aSyn pathology in animal models of PD. Low dose CO may have disease-modifying activity in PD."

CNS Disorders • Movement Disorders • Parkinson's Disease

A Study of Injection HB0025 in Adult Healthy Volunteers (clinicaltrials.gov) - P1; N=54; Not yet recruiting; Sponsor: Huabo Biopharm Co., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Trial completion date: Nov 2020 ➔ Feb 2021; Trial primary completion date: Oct 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1; N=21; Completed; Sponsor: Huabo Biopharm Co., Ltd.; Recruiting ➔ Completed; N=30 ➔ 21

Clinical • Enrollment change • Trial completion • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Jun 2020 ➔ Nov 2020; Trial primary completion date: May 2020 ➔ Oct 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor